| 1. |
Voß U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol, 2012, 214(214): 473-497.
|
| 2. |
Wang YT, Lim HY, Tai D, et al. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol, 2012, 12: 104.
|
| 3. |
Walker MM, Warwick A, Ung C, et al. The role of eosinophils and mast cells in intestinal functional disease. Curr Gastroenterol Rep, 2011, 13(4): 323-330.
|
| 4. |
Yoon H. Mast cell May be the master key to solve the mystery of pathogenesis of irritable bowel syndrome. Gut Liver, 2016, 10(3): 325-326.
|
| 5. |
Bugajev V, Bambousková M, Dráberová L, et al. What precedes the initial tyrosine phosphorylation of the high affinity IgE receptor in antigen-activated mast cell?. FEBS Lett, 2010, 584(24): 4949-4955.
|
| 6. |
Hoffmann HJ, Frandsen PM, Christensen LH, et al. Cultured human mast cells are heterogeneous for expression of the high-affinity IgE receptor FcεRI. Int Arch Allergy Immunol, 2012, 157(3): 246-250.
|
| 7. |
Osterfeld H, Ahrens R, Strait R, et al. Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol, 2010, 125(2): 469-476.e2.
|
| 8. |
Ramsay DB, Stephen S, Borum M, et al. Mast cells in gastrointestinal disease. Gastroenterol Hepatol (N Y), 2010, 6(12): 772-777.
|
| 9. |
Doyle LA, Sepehr GJ, Hamilton MJ, et al. A clinic pathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol, 2014, 38(6): 832-843.
|
| 10. |
Ortiz-Lucas M, Saz-Peiró P, Sebastián-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig, 2010, 102(11): 637-647.
|
| 11. |
Camilleri M, Di Lorenzo C. Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr, 2012, 54(4): 446-453.
|
| 12. |
Lee JW, Park JH, Park DI, et al. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci, 2010, 55(10): 2922-2928.
|
| 13. |
De Filippis D, Luongo L, Cipriano M, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain, 2011, 7: 3.
|
| 14. |
Schaeffer DF, Kirsch R, Riddell RH. Mast cells and intestinal motility disorders (mastocytic enteritis/colitis) Dig Dis Sci, 2012, 57(5): 1118-1121.
|
| 15. |
Ucmak F, Goral V, Firat U, et al. Rate of microscopic colitis and cytokine levels in patients with irritable bowel syndrome. Acta Medica Mediterranea, 2015, 31: 103-108.
|
| 16. |
Hamilton MJ, Sinnamon MJ, Lyng GD, et al. Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci USA, 2011, 108(1): 290-295.
|
| 17. |
Wang JJ, Jiang ZD, Zhang ZY, et al. Role of mast cells and protease activated receptor-2 in irritable bowel syndrome. World Chinese J Digestology, 2014, 22(3): 327-332.
|
| 18. |
Song J, Zhang L, Bai T, et al. Mast cell-dependent mesenteric afferent activation by mucosal supernatant from different bowel segments of Guinea Pigs with post-infectious irritable bowel syndrome. J Neurogastroenterol Motil, 2015, 21(2): 236-246.
|
| 19. |
Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut. Biochim Biophys Acta, 2012, 1822(1): 85-92.
|
| 20. |
Schemann M, Camilleri M. Functions and imaging of mast cell and neural axis of the gut. Gastroenterology, 2013, 144(4): 698-704. e4.
|
| 21. |
Sohn W, Lee OY, Lee SP, et al. Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. Scand J Gastroenterol, 2014, 49(1): 43-51.
|
| 22. |
Yu Y, Wu S, Li J, et al. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis, 2015, 30(1): 47-55.
|
| 23. |
Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil, 2005, 17(5): 637-642.
|
| 24. |
Di Nardo G, Barbara G, Cucchiara S, et al. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. Neurogastroenterol Motil, 2014, 26(2): 196-204.
|
| 25. |
Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut, 2010, 59(9): 1213-1221.
|
| 26. |
De Winter BY, Van Den Wijngaard RM, De Jonge WJ. Intestinal mast cells in gut inflammation and motility disturbances. Biochim Biophys Acta, 2012, 1822(1): 66-73.
|
| 27. |
De Lisle RC, Meldi L, Roach E, et al. Mast cells and gastrointestinal dysmotility in the cystic fibrosis mouse. PLoS One, 2009, 4(1): e4283.
|
